January 9, 2025 10:19 AM ESTUpdated 11:25 AM
News Briefing

Num­ab ex­tends its Se­ries C; AnaC­ar­dio rais­es $19M for its heart fail­ure drug

ENDPOINTS

Plus, news about Rheuma­Gen and Ry­bo­Dyn:

Num­ab Ther­a­peu­tics brings in $55M: The Swiss biotech ex­tend­ed its Se­ries …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis re­turns for its an­ti­co­ag­u­lant in up to $3.1B buy of Black­stone’s An­thos

Pfiz­er’s prostate can­cer da­ta leak shows promis­ing re­sults in ear­ly-stage study

Up­dat­ed: Judge halts NIH cuts na­tion­wide af­ter groups, 22 states sue

Ver­tex op­er­a­tions chief Stu­art Ar­buck­le to re­tire

Eli Lil­ly inks $630M deal for Phase 1 MASH can­di­date

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times